Ying Huang - Legend Biotech CEO Director
| LEGN Stock | USD 40.42 0.67 1.69% |
Insider
Ying Huang is CEO Director of Legend Biotech Corp
| Age | 51 |
| Address | 2101 Cottontail Lane, Somerset, NJ, United States, 08873 |
| Phone | 732 317 5050 |
| Web | https://www.legendbiotech.com |
Legend Biotech Management Efficiency
The company has return on total asset (ROA) of (0.1228) % which means that it has lost $0.1228 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2835) %, meaning that it created substantial loss on money invested by shareholders. Legend Biotech's management efficiency ratios could be used to measure how well Legend Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.3. In addition to that, Return On Capital Employed is likely to drop to -0.28. At this time, Legend Biotech's Net Tangible Assets are very stable compared to the past year. As of the 22nd of November 2024, Non Current Assets Total is likely to grow to about 368.4 M, while Total Assets are likely to drop about 938.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Angela MD | Spero Therapeutics | N/A | |
| MBA MD | Spero Therapeutics | 43 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Karen Kotz | Coherus BioSciences | N/A | |
| Marine Popoff | Hookipa Pharma | N/A | |
| James Brady | Spero Therapeutics | N/A | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Rebecca Sunshine | Coherus BioSciences | 61 | |
| McDavid Stilwell | Coherus BioSciences | 52 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| Prof MD | Hookipa Pharma | 80 | |
| Christopher Slavinsky | Coherus BioSciences | 51 | |
| Richard Hameister | Coherus BioSciences | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Andrew MBA | Monopar Therapeutics | 52 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Christine MBA | Hookipa Pharma | 59 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.12 |
Legend Biotech Corp Leadership Team
Elected by the shareholders, the Legend Biotech's board of directors comprises two types of representatives: Legend Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Legend. The board's role is to monitor Legend Biotech's management team and ensure that shareholders' interests are well served. Legend Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Legend Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James JD, General Counsel | ||
| Lori CPA, Chief Officer | ||
| Guowei Fang, Chief Development | ||
| Elaine Qian, VP Resources | ||
| Tina Carter, Corporate Lead | ||
| Steven Gavel, US Development | ||
| Marc Harrison, VP Counsel | ||
| Liz Gosen, Senior Operations | ||
| Surabhi Verma, Manager Communications | ||
| Ying Huang, CEO Director | ||
| Yuhong Qiu, Senior Affairs | ||
| Doug Wallace, Vice Operations | ||
| Alan Kick, Senior Quality | ||
| Tim Roberts, Global Officer | ||
| Joanne Choi, Senior Relations | ||
| Deborah Wong, Executive Communications |
Legend Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Legend Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.67) % | ||||
| Operating Margin | (0.44) % | ||||
| Current Valuation | 6.43 B | ||||
| Shares Outstanding | 183.45 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 51.20 % | ||||
| Number Of Shares Shorted | 15.86 M | ||||
| Price To Book | 6.53 X |
Pair Trading with Legend Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Legend Stock
| 0.74 | ME | 23Andme Holding | PairCorr |
| 0.9 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.68 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Legend Stock
| 0.48 | KZR | Kezar Life Sciences | PairCorr |
| 0.44 | MLYS | Mineralys Therapeutics, Downward Rally | PairCorr |
| 0.43 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.37 | RNXT | RenovoRx | PairCorr |
| 0.34 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share 2.851 | Quarterly Revenue Growth 0.669 | Return On Assets (0.12) | Return On Equity (0.28) |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.